A string of private equity giants including Blackstone and Carlyle are reportedly circling GlaxoSmithKline’s consumer unit in a deal which could see it valued at up to £40bn.
The post Buyout giants eye mammoth $54bn buyout of GlaxoSmithKline consumer unit: report first appeared on AltAssets Private Equity News.
